Related Experiment Video
Updated: May 26, 2026
09:28
Automated High-throughput Behavioral Analyses in Zebrafish Larvae
Published on: July 4, 2013
Measuring thigmotaxis in larval zebrafish
S J Schnörr1, P J Steenbergen, M K Richardson
1Institute of Biology, Department of Integrative Zoology, Leiden University, The Netherlands.
Behavioural Brain Research
|December 27, 2011
Summary
Researchers developed a novel assay to measure thigmotaxis, an anxiety indicator, in larval zebrafish. This validated method uses light transitions and effectively screens anxiolytic and anxiogenic drugs.
Area of Science:
- Neuroscience
- Behavioral Science
- Pharmacology
Background:
- Thigmotaxis, or wall-hugging, is a validated measure of anxiety in preclinical models.
- Existing thigmotaxis assays are not validated for larval zebrafish.
- Larval zebrafish are increasingly used in preclinical research for drug screening and behavioral studies.
Purpose of the Study:
- To develop and validate a novel thigmotaxis assay for larval zebrafish.
- To assess the response of larval zebrafish to light-to-darkness transitions.
- To confirm the assay's utility in detecting anxiolytic and anxiogenic drug effects.
Main Methods:
- A novel thigmotaxis assay was developed using a standard 24-well plate and sudden light-to-darkness transitions.
- Larval zebrafish (5 days post fertilization) were exposed to the light-to-darkness transition.
- The effects of anxiolytic (diazepam) and anxiogenic (caffeine) drugs on thigmotaxis were measured.
Main Results:
- Larval zebrafish exhibited thigmotaxis in response to sudden light-to-darkness transitions.
- Anxiolytic and anxiogenic drugs significantly altered thigmotaxis levels, validating the assay.
- Reduced light-to-darkness contrast decreased thigmotaxis, similar to anxiolytic effects.
Conclusions:
- This study presents the first validated thigmotaxis assay for larval zebrafish.
- Sudden darkness can serve as an anxiogenic stimulus for larval zebrafish.
- The assay is a cost-effective, high-throughput tool for preclinical drug screening and central nervous system research.
